Key Points

• Bristol Myers Squibb maintains a robust specialized drug portfolio and generates strong free cash flow to support its operations.

• Johnson & Johnson offers massive scale and diversification across pharmaceutical medicine and advanced medical technology segments.

• Which established healthcare giant is the more compelling addition to your portfolio?

• 10 stocks we like better than Bristol Myers Squibb ›

Choosing between two healthcare titans often comes down to a choice between specialized growth and diversified stability. Investors are currently weighing Bristol Myers Squibb (NYSE:BMY) against Johnson & Johnson (NYSE:JNJ) to see which fits better.

Bristol Myers Squibb operates as a focused biopharmaceutical company targeting high-impact areas like oncology and cardiology. In contrast, Johnson & Johnson is a global conglomerate that pairs a massive pharmaceutical division with a world-class medical device business, offering a broader reach across the entire healthcare landscape.

The case for Bristol Myers Squibb

In its latest annual report, filed for the 2025 fiscal year, Bristol Myers Squibb detailed its focus on discovering and delivering innovative medicines for serious diseases. The company is a prominent player among pharmaceutical stocks, focusing heavily on oncology, hematology, and cardiovascular health. It distributes products primarily through wholesalers and specialty pharmacies, while recently expanding into direct-to-patient offerings to streamline how patients access critical treatments.

In FY 2025, revenue reached nearly $48.2 billion, reflecting a slight year-over-year decrease of approximately 0.2%. The company reported a net income of roughly $7.1 billion during this period, which is a significant turnaround from the net loss recorded in the previous year. This improvement in profitability resulted in a net margin of about 14.6% for the fiscal year, showing the company's ability to manage costs while transitioning its product pipeline.

As of its December 2025 balance sheet, the company reported a debt-to-equity ratio of approximately 2.6x. This indicates that total debt is 2.6 times the value of shareholder equity, which shows a higher level of leverage than some industry peers. However, the company remains liquid with a current ratio of roughly 1.3x and generated nearly $12.8 billion in free cash flow, providing the cash needed to fund research and development.

The case for Johnson & Johnson

According to its latest annual report, filed for the 2025 fiscal year, Johnson & Johnson operates through two primary segments: innovative medicine and medtech. The company serves aglobal marketby delivering treatments for immunology and neuroscience alongside surgical and orthopedic tools. A major strategic shift is currently underway as the company intends to separate its orthopedics business, a move expected to be completed within the next 18 to 24 months.

In FY 2025, revenue reached approximately $94.2 billion, representing a year-over-year increase of nearly 6%. The company achieved a net income of roughly $26.8 billion, which contributed to a strong net margin of approximately 28.5%. This growth highlights the steady demand for its diverse healthcare offerings and the successful integration of newer therapies within its innovative medicine segment.

Based on its December 2025 balance sheet, Johnson & Johnson maintains a conservative debt-to-equity ratio of approximately 0.6x. This figure means the company carries roughly $0.60 of total debt for every dollar of shareholder equity, indicating a very strong financial position. With a current ratio of nearly 1.0x and free cash flow of approximately $19.7 billion, the company has ample capital to support its ongoing dividend and internal investments.

Risk profile comparison

Bristol Myers Squibb faces significant risks from government-mandated price controls, particularly following the Inflation Reduction Act, which has impacted pricing for key drugs like Eliquis. The company also deals with looming patent exclusivity losses, which often lead to rapid revenue declines as generic competitors enter the market. Furthermore, the company is managing a revived $6.7 billion lawsuit related to its Celgene acquisition and ongoing patent disputes with competitors like Cytokinetics.

Johnson & Johnson carries its own set of regulatory risks, including price-setting for major products like Stelara and Xarelto. The company is also navigating substantial exposure to complex litigation, most notably the long-standing mass tort claims related to its talc-based body powders. Additionally, the planned separation of its orthopedics business carries execution risk, especially as it competes for market share against other large pharmaceutical players like Merck and Pfizer.

Valuation comparison

Bristol Myers Squibb appears to be the more value-oriented choice, trading at a lower earnings multiple, while Johnson & Johnson commands a premium for its higher profitability.

Which stock would I buy in 2026?

Johnson & Johnson's global scale and diverse business make it a healthcare giant that's difficult to compete with. Despite being 4 times its size by market cap and generating nearly double the amount of revenue in fiscal year 2025, J&J is still growing faster than Bristol Myers Squibb, delivering 6% revenue growth last year with higher margins and less debt. It isn't just a stable blue chip company, it's one that still delivers growth potential, especially as it streamlines its portfolio, having spun off its consumer health division (now Kenvue) in 2023, with plans to separate its orthopedics segment in the next year.

But you'll have to pay a bit of a premium to own the stock, as its forward P/E is higher than both Bristol Myers Squibb's and the average for the healthcare market segment. It also offers a more modest dividend, about half that of Bristol Myers Squibb.

Still, I'd choose Johnson & Johnson in this matchup. Both companies face litigation costs, patent cliffs, and growing pains, and bringing new medical equipment and therapies to market is complex and expensive. But Johnson & Johnson has the balance sheet and size to navigate those challenges, plus an active management team that's making moves to remain nimble in an evolving landscape.

Should you buy stock in Bristol Myers Squibb right now?

Before you buy stock in Bristol Myers Squibb, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $389,154!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,406,303!*

Now, it’s worth noting Stock Advisor’s total average return is 949% — a market-crushing outperformance compared to 214% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

*Stock Advisor returns as of September 24, 2026.

Sarah Sidlow has positions in Johnson & Johnson and Pfizer. The Motley Fool has positions in and recommends Bristol Myers Squibb, Cytokinetics, Merck, and Pfizer. The Motley Fool recommends Johnson & Johnson and Kenvue. The Motley Fool has a disclosure policy.